169 related articles for article (PubMed ID: 24505595)
1. Perforating folliculitis-like reaction related to sorafenib.
Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
[No Abstract] [Full Text] [Related]
2. Delayed onset perforating folliculitis associated with sorafenib.
Batalla A; Menéndez L; Blay P; Curto JR
Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
[No Abstract] [Full Text] [Related]
3. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
4. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
Pichler M; Carriere C; Mazzoleni G; Kluge R; Eisendle K
Clin Exp Dermatol; 2014 Mar; 39(2):232-3. PubMed ID: 24330088
[No Abstract] [Full Text] [Related]
5. Sorafenib in patients with refractory or recurrent multiple myeloma.
Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
[TBL] [Abstract][Full Text] [Related]
6. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
7. Treatment of intermediate-stage hepatocellular carcinoma.
Finn RS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
[No Abstract] [Full Text] [Related]
8. A Case of Perforating Folliculitis Induced by Vemurafenib.
Shiraishi K; Masunaga T; Tohyama M; Sayama K
Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
[No Abstract] [Full Text] [Related]
9. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
[No Abstract] [Full Text] [Related]
10. The adverse effects of sorafenib in patients with advanced cancers.
Li Y; Gao ZH; Qu XJ
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):216-21. PubMed ID: 25495944
[TBL] [Abstract][Full Text] [Related]
11. Grade III hand-foot skin reaction induced by sorafenib.
Chiriac A; Coros MF; Podoleanu C; Stolnicu S
An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
[No Abstract] [Full Text] [Related]
12. Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.
Borgia F; Saitta C; Vaccaro M; Franzè MS; Lentini M; Cannavò SP
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):327-331. PubMed ID: 28825507
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
Pichard DC; Cardones AR; Chu EY; Dahut WL; Kong HH
JAMA Dermatol; 2016 Feb; 152(2):227-8. PubMed ID: 26422655
[No Abstract] [Full Text] [Related]
14. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
[TBL] [Abstract][Full Text] [Related]
15. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
[TBL] [Abstract][Full Text] [Related]
16. Transient perforating folliculitis induced by sorafenib.
Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
[No Abstract] [Full Text] [Related]
17. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
18. Sorafenib (Nexavar) for thyroid cancer.
Med Lett Drugs Ther; 2014 May; 56(1443):43-4. PubMed ID: 24869715
[No Abstract] [Full Text] [Related]
19. Sorafenib: osteonecrosis of the jaw.
Prescrire Int; 2015 Nov; 24(165):269. PubMed ID: 26688904
[No Abstract] [Full Text] [Related]
20. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
